JP2022512672A5 - - Google Patents

Info

Publication number
JP2022512672A5
JP2022512672A5 JP2021519849A JP2021519849A JP2022512672A5 JP 2022512672 A5 JP2022512672 A5 JP 2022512672A5 JP 2021519849 A JP2021519849 A JP 2021519849A JP 2021519849 A JP2021519849 A JP 2021519849A JP 2022512672 A5 JP2022512672 A5 JP 2022512672A5
Authority
JP
Japan
Prior art keywords
binding protein
antibody
use according
fused
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021519849A
Other languages
English (en)
Japanese (ja)
Other versions
JP7607556B2 (ja
JP2022512672A (ja
Filing date
Publication date
Priority claimed from EP18199879.0A external-priority patent/EP3636284A1/en
Application filed filed Critical
Publication of JP2022512672A publication Critical patent/JP2022512672A/ja
Publication of JP2022512672A5 publication Critical patent/JP2022512672A5/ja
Application granted granted Critical
Publication of JP7607556B2 publication Critical patent/JP7607556B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021519849A 2018-10-11 2019-10-11 アントラサイクリンを含む結合タンパク質-毒素融合体、および免疫腫瘍学的適用におけるその使用 Active JP7607556B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18199879.0A EP3636284A1 (en) 2018-10-11 2018-10-11 Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
EP18199879.0 2018-10-11
PCT/EP2019/077644 WO2020074724A1 (en) 2018-10-11 2019-10-11 Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications

Publications (3)

Publication Number Publication Date
JP2022512672A JP2022512672A (ja) 2022-02-07
JP2022512672A5 true JP2022512672A5 (cg-RX-API-DMAC7.html) 2022-10-21
JP7607556B2 JP7607556B2 (ja) 2024-12-27

Family

ID=63833918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021519849A Active JP7607556B2 (ja) 2018-10-11 2019-10-11 アントラサイクリンを含む結合タンパク質-毒素融合体、および免疫腫瘍学的適用におけるその使用

Country Status (12)

Country Link
US (1) US20210379194A1 (cg-RX-API-DMAC7.html)
EP (2) EP3636284A1 (cg-RX-API-DMAC7.html)
JP (1) JP7607556B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210075085A (cg-RX-API-DMAC7.html)
CN (1) CN112805037A (cg-RX-API-DMAC7.html)
AU (1) AU2019358518A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021006269A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112848A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190653A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021003136A (cg-RX-API-DMAC7.html)
PH (1) PH12021550750A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020074724A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ror1結合タンパク質を発現する細胞を培養する方法
WO2023217227A1 (zh) 2022-05-12 2023-11-16 先声再明医药有限公司 喜树碱类衍生物及配体-药物偶联物
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
BR122020025870B1 (pt) 2014-12-23 2024-01-09 Nbe-Therapeutics Ag Método para a produção de um conjugado de proteína de ligaçãofármaco
US20180028682A1 (en) 2015-02-09 2018-02-01 Nbe Therapeutics Ag Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
CA3001941A1 (en) 2015-10-30 2017-05-04 Nbe-Therapeutics Ag Anti-ror1 antibodies
US20190112385A1 (en) 2015-10-30 2019-04-18 Nbe-Therapeutics Ag Anti-mesothelin antibodies
MX2018008926A (es) * 2016-01-20 2019-01-10 Scripps Research Inst Composiciones de anticuerpo contra ror1 y métodos relacionados.
CN109311982A (zh) * 2016-01-20 2019-02-05 斯克利普斯研究所 Ror2抗体组合物和相关方法
PL3964529T3 (pl) * 2016-01-22 2025-10-27 MabQuest SA Nieblokujące przeciwciała specyficzne względem pd1
SG11201901624RA (en) * 2016-09-07 2019-03-28 Univ Canberra Lysine specific histone demethylase-1 inhibitors and uses therefor
WO2018103739A1 (zh) * 2016-12-09 2018-06-14 凯惠科技发展(上海)有限公司 抗体药物偶联物、制备方法、中间体、药物组合物及应用
JP7359700B2 (ja) * 2017-06-20 2023-10-11 ソレント・セラピューティクス・インコーポレイテッド Cd38抗体薬物コンジュゲート
US20210139579A1 (en) * 2017-07-20 2021-05-13 Nbe-Therapeutics Ag Multispecific antibody product that binds to different ror1 epitopes
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
KR20230008269A (ko) * 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules

Similar Documents

Publication Publication Date Title
JP2025163055A5 (cg-RX-API-DMAC7.html)
JP2022177090A5 (cg-RX-API-DMAC7.html)
JP2020063262A5 (cg-RX-API-DMAC7.html)
WO2021244089A1 (zh) 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用
JP2022101693A5 (cg-RX-API-DMAC7.html)
JP2023549537A5 (cg-RX-API-DMAC7.html)
HRP20241417T1 (hr) Bifunkcionalno antitijelo anti-pd-1 i anti-vegfa, njegov farmaceutski pripravak i njegova uporaba
JP2019531084A5 (cg-RX-API-DMAC7.html)
JP2017531028A5 (cg-RX-API-DMAC7.html)
CN113412281B (zh) Btn3a结合蛋白及其用途
JP2020534830A5 (cg-RX-API-DMAC7.html)
JP2023539501A5 (cg-RX-API-DMAC7.html)
JP2013527761A5 (cg-RX-API-DMAC7.html)
BR112020012464A2 (pt) molécula de ligação ao antígeno biespecífica; proteína de fusão recombinante, receptor de antígeno quimérico, célula, sequência de ácidos nucleicos, vetor, célula hospedeira, método para preparar uma molécula de ligação ao antígeno biespecífica, proteína de fusão recombinante ou receptor de antígeno quimérico, composição farmacêutica, uso de uma molécula de ligação ao antígeno biespecífica, método para tratamento de uma doença em um paciente que necessita de tratamento, método para avaliar a presença de um analito-alvo em uma amostra, método para imageamento de um sítio de doença em um indivíduo, método para diagnóstico de uma doença ou afecção médica em um indivíduo, anticorpo, fragmento de anticorpo ou molécula de ligação ao antígeno, kit e método para diagnóstico de um indivíduo que sofre de câncer, ou uma predisposição para o mesmo, ou para fornecer um prognóstico da afecção de um indivíduo, método para eliminar ou inibir o crescimento de uma célula que expressa ror1 e egfr in vitro ou em um paciente
JP2021508707A5 (cg-RX-API-DMAC7.html)
JP2020521478A5 (cg-RX-API-DMAC7.html)
JP2021513848A5 (cg-RX-API-DMAC7.html)
JP2020534012A5 (cg-RX-API-DMAC7.html)
FI3941946T3 (fi) Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja
JP2022553922A5 (cg-RX-API-DMAC7.html)
CN116940598A (zh) 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
JP2005528914A5 (cg-RX-API-DMAC7.html)
JP2018528759A5 (cg-RX-API-DMAC7.html)
JP2024537323A5 (cg-RX-API-DMAC7.html)
JP2023542900A5 (cg-RX-API-DMAC7.html)